Creative ways needed to fight complacency, wishful thinking, insularity before next pandemic: President Tharman
SINGAPORE – Barely five years after Covid-19 first hit the world, it is at risk of forgetting the lessons, and the greatest challenge now is complacency, wishful thinking and insularity, said President Tharman Shanmugaratnam.
It has to counter that challenge creatively and avoid further polarisation, he said.
'We have to do so through arrangements that appeal to nations' sense of self-preservation, and which recognise the practical reality that we can only prevent and prepare for the next pandemic through a major step-up in internationally coordinated investments and actions.'
Speaking at a high-level networking dinner hosted by Temasek Foundation on May 6, Mr Tharman said scientists have made clear that the next major pandemic is a matter of when, not if, and it could come in 10 years or next year. There is thus much work ahead.
The world has to first reclaim lost ground and rebuild local healthcare systems as the Covid-19 pandemic had set them back by more than just the first few years of that event. It has to continue to invest at much higher levels in the global health ecosystem, especially in pandemic prevention and preparedness, as well as strengthen international and regional cooperation, Mr Tharman said.
Held at the Pan Pacific Singapore hotel, the dinner coincides with the Philanthropy Asia Summit 2025, which is taking place from May 5 to 7. It brings together leaders from philanthropy, government and the private sector to explore opportunities for advancing health and well-being in Asia.
Among the guest speakers is Dr Tedros Adhanom Ghebreyesus, the director-general of the World Health Organisation (WHO).
Congratulating him on reaching the agreement on the WHO's pandemic treaty on April 16, Mr Tharman said the pact lays the foundation for the world to address major gaps in the global health ecosystem, and particularly the huge inequities in access to vaccines and therapeutics that were seen during the Covid-19 pandemic.
In research and development, much work needs to be done downstream to make vaccines and treatments affordable and accessible, he said.
This includes developing vaccines that are needle-free to address the challenge of the need for skilled manpower to administer them, and which do not need to be kept below freezing point.
Developing a globally distributed manufacturing ecosystem for vaccines and treatments is also very important, he added.
Mr Tharman said the WHO has been working to seed and grow collaboration in these and other areas.
'Regional disease surveillance and control networks have also become crucial pillars of our collective defence,' he said.
For instance, the Africa Centres for Disease Control and Prevention coordinates surveillance of 55 countries serving 1.3 billion people, while the European Centre for Disease Prevention and Control strengthens preparedness in the European Union.
In Singapore, the National Environment Agency's Environmental Health Institute, designated as a WHO Collaborating Centre for Reference and Research of Arbovirus and their Associated Vectors, supports regional capacity and capability for the surveillance and control of arboviral diseases, which are spread by arthropods such as insects and mites.
Asean, too, is stepping up in safeguarding regional health security.
'The gradual pullback in spending on international development and global health is now a new reality for multilateral institutions like the WHO, as well as for the other plurilateral and non-governmental bodies that comprise the whole health ecosystem,' said Mr Tharman.
A resilient financing ecosystem for global health needs to be developed within these constraints, he said.
'We cannot wait for the most ideal multilateral architecture to be rebuilt, and we are not even sure what it would look like,' he said.
'We will therefore have to work with broad coalitions of the willing.'
These are broad coalitions of governments, together with plurilateral bodies like the Coalition For Epidemic Preparedness Innovation, for instance, philanthropic organisations and leading businesses, working together with multilateral organisations like the WHO.
World Health Organisation director-general Tedros Adhanom Ghebreyesus (left) chatting with President Tharman Shanmugaratnam at the Temasek Foundation networking dinner on May 6.
ST PHOTO: GAVIN FOO
Multilateral institutions can help mobilise these coalitions, and work jointly with them to scale up efforts to prevent and prepare for the next pandemic, Mr Tharman said.
At the dinner, Dr Tedros said Singapore has come a long way since it gained independence in 1965 – the year he was born – and now enjoys one of the world's longest life expectancies, has one of the world's most advanced health systems, and is one of the world's most advanced economies.
He said countries invest billions in protecting themselves from attacks by other countries or terrorist groups, but relatively little on protecting themselves from an attack from an invisible enemy. However, health security is economic security, and both must be balanced.
A lot of the WHO's work goes unseen, including the unglamorous technical work of bringing global experts together to distil the latest scientific evidence into guidance, and helping countries to strengthen their health systems, Dr Tedros said. But the WHO cannot do it alone.
It works closely with a huge range of partners, including many philanthropists, who are making a huge impact on global health.
Temasek Foundation's executive director and CEO, Mr Ng Boon Heong, said that the foundation, as a non-state actor of the WHO, has pledged up to US$10 million (S$13 million) to co-curate programmes and projects to improve health outcomes in Asia in the areas of pandemic preparedness, maternal and child health, digital health, and science and innovation.
The WHO works with non-state actors such as non-governmental organisations, philanthropic groups and academic institutions to advance global health.
Joyce Teo is a senior health correspondent at The Straits Times, and the host of the ST Health Check podcast.
Join ST's WhatsApp Channel and get the latest news and must-reads.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Straits Times
4 hours ago
- Straits Times
Used in Covid-19 shots, mRNA may help rid the body of HIV
The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. PHOTO: UNSPLASH Used in Covid-19 shots, mRNA may help rid the body of HIV NEW YORK - The technology that powered Covid-19 vaccines may also lead scientists to a cure for HIV. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary and so far has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid-19 vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting HIV. Dr Sharon Lewin, director of the Doherty Institute at the University of Melbourne, who led the study, called mRNA a 'miraculous' tool 'to deliver things that you want into places that were not possible before.' Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr, have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also cancelled a nearly US$600 million (S$773.72 million) contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. 'The fear right now is not rational,' Dr Lewin said, adding that 'mRNA vaccines have been given to millions of people around the world, so we have a very good understanding of their risks.' The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. Other uses could involve providing proteins missing from those with certain diseases or correcting genetic errors. Dr Frauke Muecksch, a virologist at Heidelberg University in Germany who was not involved in the work, called mRNA a 'promising, absolutely powerful technology.' Although most people may have only heard of mRNA's use in science during the pandemic, scientists have been working with it for more than 20 years, she said. 'I think it's not just therapeutically very powerful, but also for basic science, for research, it opens up a lot of avenues,' she added. Potent antiretroviral drugs can now control HIV, suppressing it to undetectable levels. Still, minute amounts of the virus lie dormant in so-called reservoirs, waiting for an opportunity to resurge. A cure for HIV would involve ferreting out all of this virus and destroying it, a strategy that has been called 'shock and kill.' A significant hurdle is that the virus lies dormant in a particular type of immune cell, called a resting CD4 cell. Because these cells are inactive, they tend to be unresponsive to drugs. The few drugs scientists have previously used to rouse the virus in these cells were not specific to HIV and had unwanted side effects. 'It's fair to say the field's been a little bit stuck,' said Dr Brad Jones, a viral immunologist at Weill Cornell Medicine who was not involved in the latest research. In 2022, Dr Jones and his colleagues found that the immune boost from the mRNA vaccines awakened latent HIV in people living with the virus. (Other research has shown that mRNA vaccines also activated dormant viruses including Epstein Barr.) 'You get just a little bit of a gentle nudge with some of these vaccines, and it's enough to coax some of these latent viruses out so they can be killed,' Dr Jones said. Dr Lewin and her colleagues had for years experimented with other ways to activate HIV, but had no luck in resting cells. Seeing the success of the Covid-19 vaccines, which used lipid nanoparticles – tiny spheres of fat – containing mRNA, her team tested similar particles. They used the particles to deliver two different sets of molecules: Tat, which is adept at switching HIV on, and CRISPR, a tool that can 'edit' genes. The researchers showed that in resting immune cells from people living with HIV, the approach coaxed the virus out of dormancy. 'It's very, very hard to deal with these cells, so I think this really targeting the right population of cells is what makes this paper special,' Dr Muecksch said. It's unclear whether the new approach can successfully awaken all of the dormant HIV in the body, and what side effects it might produce. Dr Lewin said that 'mRNA will almost certainly have some adverse effects, as every drug does, but we will investigate that systematically, as we do for any new drug.' In this case, she said, side effects may be more acceptable to people living with HIV than having to take medications for the rest of their lives. The researchers plan to test the method in HIV-infected animals next, before moving into clinical trials. NYTIMES Join ST's Telegram channel and get the latest breaking news delivered to you.


Independent Singapore
2 days ago
- Independent Singapore
Australian FB page linking Bill Gates' SG trip with vaccine mandate fact-checked; MOH debunks claims
SINGAPORE: Following an Australian Facebook account's connection last month between the recent visit to Singapore of billionaire businessman Bill Gates and a reported vaccine mandate, the Ministry of Health (MOH) issued a clarification to debunk this. 'There are social media posts claiming that Singapore has enacted laws to mandate vaccines and jail unvaccinated individuals following Mr Bill Gates' recent visit to Singapore. This is false. Singapore has not passed any laws on vaccinations after Mr Gates' recent visit to Singapore,' wrote MOH in a statement on Jun 3. Moreover, AFP has also fact-checked the post put up by the page, Catholic Perspective, on May 12, as containing falsehoods. The page had shared a link to an article from a site called The People's Voice, the headline of which reads 'Singapore Passes Law to Mandate Vaccines and Jail the Unvaccinated—Days After Bill Gates' High-Level Visit.' On Jun 4, AFP characterised the site as dubious and noted that it had fact-checked The People's Voice several times in the past when it amplified misinformation concerning the COVID-19 pandemic. Last year, when an article on the site claimed that the World Health Organization (WHO) and Mr Gates were forcing people to get vaccinated, AFP issued another fact-check, which can be found here . The article from The People's Voice carried a photo of Mr Gates shaking hands with Singapore Prime Minister (PM) Lawrence Wong, as well as another of PM Wong with Tedros Ghebreyesus, the secretary-general of the WHO. The founder of Microsoft visited Singapore in early May and spoke at the Philanthropy Asia Summit, where he announced that the Gates Foundation is opening an office in Singapore, its first in Southeast Asia, with support from the Singapore Economic Development Board (EDB). In 2000, together with his then-wife, he created the foundation, one of the largest charities around the globe. It focuses on development and has spent billions of dollars on public health endeavours across the globe. 'Asian innovation is part of the reason why I am so excited about the progress we can make in health. Some of the lower-cost vaccines are produced in India and Indonesia, but beyond cost, it is more about the cutting-edge work that can be found in the region,' he said in his speech. PM Wong wrote in a Facebook post that he and Mr Gates 'had a wide-ranging conversation on the challenges ahead, from clean energy to vaccine development. Singapore looks forward to working closely with the Gates Foundation to advance innovation and improve lives — here in Asia and around the world.' /TISG Read related: 'Concerned Citizen' from 'Healing the Divide' wants Bill Gates to be investigated under FICA
Business Times
2 days ago
- Business Times
Singapore Paincare up 12.1% as Sias urges shareholders to await IFA report
[SINGAPORE] Shares of Singapore Paincare rose on Thursday (Jun 5), a day after the Securities Investors Association (Singapore), or Sias, said the medical services company could be worth more than double its privatisation offer price. As at 4.19 pm, the counter was trading at S$0.176, 12.1 per cent or S$0.019 above the previous closing price of S$0.157 on Wednesday, with 15.2 million shares transacted. This was its highest price in the year to date. It closed on Thursday 8.3 per cent or S$0.013 higher at S$0.17, with 17.3 million shares having changed hands. On Wednesday, Sias urged minority shareholders of Singapore Paincare to hold off selling their shares amid an acquisition bid from Advance Bridge Healthcare, a management consultancy for healthcare services. Sias noted that the company could be worth around S$0.36 to S$0.37 a share, more than double the S$0.16 a share privatisation offer price. It recommended that shareholders wait and refrain from taking action until the report by the independent financial adviser (IFA) is released. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'If the shares are sold on the open market, shareholders who sold will not have recourse if there is subsequent upward revision in the offer price,' Sias warned. There have been past instances when shareholders sought slight gains and sold their shares on the open market before the IFA issued its report, it noted. Moreover, the S$0.37 per share offer price is at a 'slight discount' to the company's audited net asset value (NAV) per share of S$0.166 as at Jun 30, 2024, it said. The association highlighted that Singapore Paincare made its July 2020 trading debut during Covid-19 with an initial public offering (IPO) price of S$0.22 per share, when valuations were depressed and when the Straits Times Index (STI) was trading at around 2,500 points. The IPO price of S$0.22 was a 123 per cent premium to the group's unaudited NAV per share of about S$0.0986 on Dec 31, 2019, based on the post-placement share capital and after adjusting for net proceeds due to the company from the placement. 'It now wishes to delist at S$0.16 per share when the STI is trading at around 3,900 points... If the same IPO premium were to be applied now, the privatisation price should be around S$0.36 to S$0.37,' Sias said. 'For a delisting to take place, the IFA has to conclude that the offer is both fair and reasonable... it would therefore be advisable to wait for the IFA's opinion.'